Vasomune Therapeutics Completes Enrollment of Phase 2a Study of Pegevongitide (AV-001) in Patients Hospitalized with Pneumonia/ARDS
🤖 D.R.A.F.T. Summary
Vasomune Therapeutics Completes Enrollment of Phase 2a Study of Pegevongitide (AV-001) in Patients Hospitalized with Pne
Enrollment milestone advances the FDA Fast Track-designated program toward data review and analysis TORONTO — Vasomune Therapeutics Inc. (“Vasomune”), a clinical-stage biopharmaceutical company developing medicines that target endotheliopathy and vascular leak, today announced the completion of patient enrollment in AV001-004 (NCT05123755), its randomized, double-blind, placebo-controlled Phase 2a clinical study evaluating Pegevongitide (AV-001) in patients hospitalized […]
Outlets covering this story
Financial Post
CENTER
Only one perspective covered this story — no diversity detected
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →